However, the PAR-1 inhibitor increased the risk of moderate or severe bleeding, including intracranial hemorrhage; thus, vorapaxar should not be used in persons with history of stroke, transient ischemic attack or intracranial hemorrhage (199). This evidence concerns the gene F2R and intracranial hemorrhage.